Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | PPM1B | O75688 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273372 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL11175481 | 0.94 | LGALS9 (0.54) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL11175487 | 0.94 | LGALS9 (0.54) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL11169728 | 0.92 | ALDH1A1 (0.51) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL27988153 | 0.92 | LGALS9 (0.53) | ALDH1A1HTTSYNJ2TYMPLGALS9 | |
| SCHEMBL9245476 | 0.91 | ALDH1A1 (0.49) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL26455064 | 0.91 | ALDH1A1 (0.49) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL9245472 | 0.91 | ALDH1A1 (0.49) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL20691410 | 0.89 | ALDH1A1 (0.51) | ALDH1A1TDP1HTTMAPK1POLB | |
| SCHEMBL15267379 | 0.89 | ALDH1A1 (0.48) | ALDH1A1TDP1HTTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4378369-A | HYPOGLYCEMIC, ANTIDIABETIC | SANDOZ, INC. (US) | 1983-03-29 | — | — | US | claimed |
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2021-01-14 | — | — | US | disclosed |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | OPKO PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | OPKO PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3500583-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO Pharmaceuticals, LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2019-06-20 | — | — | US | disclosed |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2019-06-20 | — | — | US | disclosed |
| WO-2018035050-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035050-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2005075490-A2 | SYNTHESIS OF POLYSULFATED URONIC ACID GLYCOSIDES | IVAX CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| US-4378369-A | HYPOGLYCEMIC, ANTIDIABETIC | SANDOZ, INC. (US) | 1983-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | ALDH1A1 1443/4885TDP1 4450/4885HTT 2286/4885 |
| US-10829509-B2 | Pure heptasulfated disaccharides having improved oral bioavailability | SI, GYS1, UGGT1 | ALDH1A1 1443/4885TDP1 4450/4885HTT 2286/4885 |
| US-20190185503-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | ALDH1A1 1443/4885TDP1 4450/4885HTT 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.